Open

IDH-Wildtype Glioblastoma Treatment Study

In this study, we will find out if a new experimental pill called ropidoxuridine can help improve the treatment of a brain cancer called IDH-Wildtype Glioblastoma. We want to see how well it works when used with radiation therapy.

Age & Gender

18 years ~ 99 years
Male, Female, Gender Inclusive

Visit Availability

Standard business hours (M-F, 8-5)

Location

North Carolina (Statewide)

What will be asked of you

You will meet with the study team to sign the consent form and conduct eligibility tests. If you are eligible, you will take a set dose of ropidoxuridine. You will take this medication every weekday for 7 weeks while receiving radiation therapy. Your tumor will be checked with scans. After finishing treatment, you will follow up with your physician in clinic every 2 to 3 months.

In-person visits:
11, possibly more for long-term follow up

Total length of participation:
About 7 weeks of treatment, follow ups per standard of care

Looking for Specific Volunteers

Able to participate:

You have a confirmed supratentorial glioblastoma wt-IDH classification (with unMe-MGMT promoter)
You have not had radiation, electric field, or systemic therapy

Not eligible if:

You have another type of cancer that needs treatment within the next 6 months.
You use a proton pump inhibitors and histamine-2 blockers
You are not able to swallow oral medication or gastrointestinal disorder that might affect drug absorption
You are pregnant or breastfeeding
You have an ongoing bacterial, viral, or fungal infection requiring treatment

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Soma Sengupta
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Brain and Other Nervous System)

IRB Number

24-1411

ClinicalTrials.gov

NCT06359379

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.